Patent ID: 8648175

Claim:
A stable pharmaceutical composition of erythropoietin (EPO), which comprises: a. a therapeutically effective amount of EPO, b. a pharmaceutically acceptable pH buffering system, c. polyvinylpyrrolidone (PVP), d. optionally, an isotonifying agent, c. optionally, one or more pharmaceutically acceptable excipient(s) selected from the group consisting of polyols, hydroxypropylcellulose, methylcellulose, macrogol esters and ethers, glycol and glycerol esters, and amino acids, and f. optionally, a poloxamer as an additional stabilizer wherein the polyvinylpyrrolidone (PVP) and the optional poloxamer are the sole stabilizers for the stabilization of the erythropoietin (EPO) and wherein the composition is free of serum proteins, other than EPO, derived from human and/or animal origin.